H

ello, everyone, and how are you today? We are doing just fine, thank you, since a warm and shiny sun is enveloping the quiet Pharmalot campus. Our short person has left for the local schoolhouse and our mascots are comfortably snoozing in their respective corners. As for us, we are, as usual, keeping busy by looking for interesting items and having interesting conversations. Have something to say? Drop us a line. Meanwhile, here are some tidbits. Hope you conquer the world today …

Spark Therapeutics (ONCE), whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug outside the U.S. to Novartis (NVS) for up to $170 million, Reuters notes. Spark will keep U.S. rights to Luxturna, which is the first approved gene therapy for an inherited disease. The company plans to launch the one-time treatment in March, charging an unprecedented $850,000.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.